Carbonic anhydrase 9 (CAIX) (CAIX)

Carbonic anhydrase 9 (CAIX) is a transmembrane zinc metalloenzyme that plays a critical role in maintaining pH homeostasis within the tumor microenvironment [3, 7]. It is primarily regulated by hypoxia-inducible factor 1-alpha (HIF-1α) and is highly overexpressed in various solid tumors, most notably clear cell renal cell carcinoma (ccRCC), while remaining largely absent in normal tissues except for the gastrointestinal tract [1, 2, 13]. By catalyzing the reversible hydration of carbon dioxide into bicarbonate and protons, CAIX facilitates the acidification of the extracellular space, which promotes tumor cell survival, migration, and invasion under hypoxic conditions [2, 8, 15]. In the context of immune-mediated targeting, CAIX serves as a strategic antigen for monoclonal antibodies, chimeric antigen receptor (CAR) T-cell therapies, and bispecific molecules [1, 5, 11]. These therapies aim to exploit the tumor-specific expression of CAIX to induce direct cell killing via antibody-dependent cellular cytotoxicity (ADCC) or T-cell activation, or to deliver cytotoxic payloads and radionuclides directly to the tumor site [1, 8, 13]. Clinical development has focused on agents like girentuximab and various CAR-T constructs, though challenges such as on-target off-tumor toxicity in the bile ducts and stomach must be managed [1, 3, 9]. Overall, CAIX represents a promising target for precision oncology, particularly in aggressive, hypoxic cancers where it acts as both a functional driver and a diagnostic biomarker [7, 13, 14].

Other names

CA9MNG250Renal cell carcinoma-associated antigen G250Carbonate dehydratase IX

Carbonic anhydrase inhibition, Antibody-dependent cellular cytotoxicity (ADCC), T-cell mediated cytotoxicity, and targeted delivery of radionuclides or cytotoxics.